Highlights Molecular Partners AG

Equities

MOLN

CH0256379097

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
3.36 ^CHF	+5.00%		-0.30%	-2.33%

Mar. 15	Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
Mar. 15	Molecular Partners Swings to Loss in FY23; Revenue Down	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecular Partners Swings to Loss in FY23; Revenue Down	Mar. 15	MT
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
US Court Dismisses Putative Class Action Against Molecular Partners	Mar. 03	MT
Molecular Partners, Orano Med Team Up to Develop Radio-DARPin Therapeutics Against Cancer	Jan. 08	MT
Molecular Partners AG and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	Jan. 05	CI
Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting	Dec. 10	CI
Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	Nov. 03	CI
Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition	Nov. 02	CI
Molecular Partners AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Molecular Partners Turns to Loss in H1; Revenue Slides Down	23-08-24	MT
Molecular Partners AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Molecular Partners AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Molecular Partners AG to Present Additional Preclinical Data Supporting the Company's Radio Darpin Therapy Platform At AACR	23-04-14	CI
Molecular Partners Swings to Attributable Profit in FY22	23-03-10	MT
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Molecular Partners Presents New Preclinical Data Supporting Its Radio Darpin Therapy Platform	23-02-28	CI
Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia	23-01-16	CI
Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML	22-12-12	CI
Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors	22-11-10	CI
Molecular Partners Q3 Loss Swells as Revenue Falls	22-10-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Molecular Partners AG

Equities

MOLN

CH0256379097

Highlights

Filters